×
News Home

Denali Therapeutics Inc (DNLI) Stock: What Does the Chart Say Tuesday?

Tuesday, May 17, 2022 04:34 PM | InvestorsObserver Analysts
Denali Therapeutics Inc (DNLI) Stock: What Does the Chart Say Tuesday?

The market has been neutral on Denali Therapeutics Inc (DNLI) stock recently. DNLI gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Denali Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on DNLI!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With DNLI Stock Today?

Denali Therapeutics Inc (DNLI) stock is trading at $25.12 as of 4:00 PM on Tuesday, May 17, an increase of $1.85, or 7.95% from the previous closing price of $23.27. The stock has traded between $23.72 and $25.17 so far today. Volume today is less active than usual. So far 333,202 shares have traded compared to average volume of 556,230 shares.

More About Denali Therapeutics Inc

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. Click Here to get the full Stock Report for Denali Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App